Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02508155 | A Study of MEDI7352 in Painful Osteoarthritis of the Knee | PHASE1 | COMPLETED | 132 | — | — | Nov 17, 2015 | Dec 23, 2020 | Apr 15, 2021 | 6 | Germany, Sweden +1 |
Adverse events, serious adverse events,
| Arm | Type | Description |
|---|---|---|
| MEDI7352 IV | EXPERIMENTAL | Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses. |
| IV Placebo | PLACEBO_COMPARATOR | Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses. |
| MEDI7352 Subcutaneous Injection | EXPERIMENTAL | 1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort. |
| Subcutaneous Placebo | PLACEBO_COMPARATOR | 1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort. |
| Name | Type | Description |
|---|---|---|
| MEDI7352 for IV infusion | BIOLOGICAL | MEDI7352 for IV infusion |
| Placebo for IV infusion | BIOLOGICAL | IV Placebo infusion |
| MEDI7352 for Subcutaneous Injection | BIOLOGICAL | MEDI7352 for subcutaneous injection |
| Placebo for Subcutaneous Injection | BIOLOGICAL | Subcutaneous Placebo Injection |
Inclusion Criteria: * Male and female subjects with painful osteoarthritis (OA) of the knee. Female subjects must be postmenopausal or surgically sterile. * Body weight between 50kg and 145kg * Willing and able to comply with the requirements of the protocol Exclusion Criteria: * Current treatmen...